Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review.
Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Rowin EJ, Maron MS, Sherrid MV.
J Am Coll Cardiol. 2022 Feb 1;79(4):372-389. doi: 10.1016/j.jacc.2021.12.002.
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.
Ho CY, Mealiffe ME, Bach RG, Bhattacharya M, Choudhury L, Edelberg JM, Hegde SM, Jacoby D, Lakdawala NK, Lester SJ, Ma Y, Marian AJ, Nagueh SF, Owens A, Rader F, Saberi S, Sehnert AJ, Sherrid MV, Solomon SD, Wang A, Wever-Pinzon O, Wong TC, Heitner SB.
J Am Coll Cardiol. 2020 Jun 2;75(21):2649-2660. doi: 10.1016/j.jacc.2020.03.064.
Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review.
Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Dearani JA, Rowin EJ, Maron MS, Sherrid MV.
J Am Coll Cardiol. 2022 Feb 1;79(4):390-414. doi: 10.1016/j.jacc.2021.11.021.
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4.
Masri A, Sherrid MV, Abraham TP, Choudhury L, Garcia-Pavia P, Kramer CM, Barriales-Villa R, Owens AT, Rader F, Nagueh SF, Olivotto I, Saberi S, Tower-Rader A, Wong TC, Coats CJ, Watkins H, Fifer MA, Solomon SD, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Sohn RL, Wohltman A, Maron MS; REDWOOD-HCM Investigators.
J Card Fail. 2024 Nov;30(11):1439-1448. doi: 10.1016/j.cardfail.2024.02.020. Epub 2024 Mar 15.
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM.
Desai MY, Nissen SE, Abraham T, Olivotto I, Garcia-Pavia P, Lopes RD, Verheyen N, Wever-Pinzon O, Wolski K, Jaber W, Mitchell L, Davey D, Myers J, Rano T, Bhatia V, Zhong Y, Carter-Bonanza S, Florea V, Aronson R, Owens AT; ODYSSEY-HCM Investigators.
JACC Heart Fail. 2025 Feb;13(2):358-370. doi: 10.1016/j.jchf.2024.11.013.
Hypertrophic cardiomyopathy: the future of treatment.
Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB.
Eur J Heart Fail. 2020 Feb;22(2):228-240. doi: 10.1002/ejhf.1715. Epub 2020 Jan 9.
Current management of hypertrophic cardiomyopathy.
Sikand N, Stendahl J, Sen S, Lampert R, Day S.
BMJ. 2025 May 27;389:e077274. doi: 10.1136/bmj-2023-077274.
Unveiling the complexity of nonobstructive hypertrophic cardiomyopathy.
Ordine L, Polizzi R, Canciello G, Borrelli F, di Napoli S, Moscano L, Napolitano B, Martorano R, Spinelli A, Lombardi R, Esposito G, Losi MA.
Heart Fail Rev. 2025 Dec;30(6):1141-1153. doi: 10.1007/s10741-025-10535-w. Epub 2025 Jun 14.
Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic Cardiomyopathy.
Desai MY, Maurizi N, Biagini E, Charron P, Fernandes F, González-López E, van Haelst PL, Haugaa KH, Kramer CM, Meder B, Michels M, Owens A, Yuasa S, Elliott P.
JACC Heart Fail. 2025 Nov;13(11):102658. doi: 10.1016/j.jchf.2025.102658. Epub 2025 Sep 24.
Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored Until Now.
Maron BJ, Rowin EJ, Maron MS, Braunwald E.
Am J Med. 2017 Feb;130(2):119-123. doi: 10.1016/j.amjmed.2016.09.015. Epub 2016 Oct 14.
